Cara Therapeutics (CARA) to Continue KALM-1 Phase 3 Trial Of KORSUVA as Planned
Tweet Send to a Friend
Cara Therapeutics, Inc. (Nasdaq: CARA) announced the completion of an interim statistical analysis of its pivotal KALM-1 Phase 3 trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
